

ELEKTA ANNOUNCES NEW CANCER CARE SOLUTIONS AND HIGHLIGHTS PERSONALIZED EFFICIENCY AT ASTRO 2007

PRESS RELEASE

Atlanta, Georgia, October 18, 2007

Elekta, a global leader in radiation oncology and non-invasive neurosurgery solutions, will feature advances in cancer care at the 49th Annual Meeting of The American Society for Therapeutic Radiology and Oncology (ASTRO) that dramatically reduce treatment times and increase efficiency.

The meeting will be held October 28 - November 1 at the Los Angeles Convention Center (Los Angeles, California, USA). Elekta will showcase innovative offerings that optimize productivity and workflow, empowering health care professionals to spend more time on patient care. One important highlight will be the announcement of a new Elekta solution for clinical Volumetric Intensity Modulated Arc Therapy* (VMAT) that more precisely targets tumors and protects surrounding healthy tissue, while drastically reducing radiation therapy treatment times.

Jay Hoey, Executive Vice President Product Creation at Elekta and CEO of IMPAC Medical Systems, an Elekta company, will unveil this improvement over existing Intensity Modulated Radiation Therapy technologies at noon (PDT) October 28 on Elekta booth 1719.

Innovation on display at several Elekta Group booths

More than 11,000 domestic and international participants are expected at the 2007 ASTRO meeting. Elekta, an Ambassador-level sponsor of the event, will feature a wide range of products from the Elekta family of companies all of which highlight personalized efficiency.

"These Elekta innovations represent a singular focus on personalized efficiency – optimizing every step of the care process, to ensure care is focused on the patient and not on the technology," says Joseph K. Jachinowski, President and CEO, Elekta North America.

Further demonstrating its commitment to personalized efficiency, Elekta will showcase:

- Elekta Synergy[®], the market-leading multi-functional Intensity Modulated and Image Guided Radiation Therapy (IMRT and IGRT) system that provides automated workflow tools and 3D volumetric imaging at the time of treatment.
- Leksell Gamma Knife[®] Perfexion[™], the latest generation of Gamma Knife surgery for cranial radiosurgery and the only radiation technology that has a specific indication for the treatment of brain metastases.
- Elekta Axesse[™], a whole body, robotic image-guided stereotactic treatment management system. This cutting edge technology streamlines workflow through a combination of advanced robotics, integrated software and patientfriendly immobilization.

Oncology information products demonstrating personalized efficiency will be on display at IMPAC booth 1609. MOSAIQ™, image-integrated electronic medical record,



MOSAIQ[™] RTP* suite for treatment planning, the MOSAIQ[™] Oncology PACS (Picture Archiving and Communications System), an oncology specific PACS and SYNERGISTIQ[™] will be showcased. SYNERGISTIQ is a unified therapy treatment console environment that eliminates bottlenecks associated with simultaneously managing otherwise complex image-quidance and delivery processes.

Medical Intelligence, an Elekta Company, also will be demonstrating advancements in patient immobilization during radiation treatments at booth 1701. In addition, the iBEAM® evo Couchtop – the next generation of homogenous carbon fiber couchtops – will be on display, as well as, the new fully robotic HexaPOD $^{\text{TM}}$ evo** positioning table for efficient and accurate 6D patient positioning.

These and other Elekta solutions demonstrate Elekta's commitment to making cancer care easier for therapists and patients. "The combination of Elekta and IMPAC clinical solutions are simplifying and streamlining the treatment process to create a better experience for patients, as well as, enhance the efficiency of the clinician, demonstrating our commitment to personalized efficiency," says Jachinowski.

Users' Meeting

Concurrent with the ASTRO show will be the IMPAC and Elekta Radiation Oncology Users' Meeting, Saturday, October 27 at the Pasadena Civic Center (Pasadena, California, USA). Expected to draw more than 1,000 IMPAC and Elekta users, the meeting will focus on optimizing personalized efficiency within the clinic through advanced and dynamic innovations. Participants will attend sessions on EMR workflow featuring MOSAIQ, efficiency and advancements in IGRT and stereotaxy, and business and economic solutions.

For further information, please contact:

Media inquiries: Michelle Lee, PR and Advertising Manager, Tel: +1 770-670-2447,

e-mail: michelle.lee@elekta.com

Global Marketing inquiries: Peter Gaccione, Vice President, Global Marketing, Tel: +1 770-670-2380,

e-mail: peter.gaccione@elekta.com

Investor inquiries: Peter Ejemyr, Group VP Corporate Communications, Tel: +46 733 611 000 (mobile),

e-mail: peter.ejemyr@elekta.com

About Elekta

Elekta is an international medical technology group, providing oncologists, radiation therapists, neurosurgeons and many other medical specialists with state of the art tools to fight serious disease.

Elekta provides advanced clinical solutions, comprehensive management and information systems as well as services for improved cancer care and management of brain disorders.

Elekta's systems and solutions are used in over 4,500 hospitals around the world. Clinical and information management solutions include, among others, Leksell Gamma Knife® for non-invasive treatment of brain disorders, Elekta Axesse™ and Elekta Synergy® for stereotactic and image guided radiation therapy and radiosurgery as well as the MOSAIQ™ suite of software for image-enabled EMR and efficient management of clinical and patient data.

With over 2,000 employees globally, the corporate headquarter is located in Stockholm, Sweden and the company is listed on the Nordic Exchange under the ticker EKTAb. More information about Elekta can be found at www.elekta.com.

^{*}Volumetric Intensity Modulated Arc Therapy (VMAT) and MOSAIQ $^{\text{TM}}$ RTP are works in progress and not commercially available

^{**}HexaPOD™ evo is pending 510(k) clearance from the FDA